Suicidality and epilepsy: A neuropsychobiological perspective

Epilepsy and Behavior

Volumn 22, Issue 1, 2011, Pages 77-84

  Hecimovic, Hrvoje ^a   Salpekar, Jay ^b   Kanner, Andres M ^c   Barry, John J ^d  

^a KBC Zagreb   (Croatia)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety disorder; Glutamate; Hypothalamic pituitary axis; Major depressive disorder; Serotonin receptors

Indexed keywords

4 AMINOBUTYRIC ACID; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; IMIPRAMINE; NEUROTRANSMITTER; NORADRENALIN; PAROXETINE; SEROTONIN; SERTRALINE;

ADOLESCENT DISEASE; CHILDHOOD DISEASE; COGNITIVE THERAPY; DEPRESSION; EPILEPSY; FAMILY HISTORY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IATROGENIC DISEASE; MENTAL DISEASE; NEUROBIOLOGY; NEUROPSYCHOLOGY; NONHUMAN; REVIEW; RISK ASSESSMENT; SCREENING TEST; SEROTONINERGIC SYSTEM; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE;

ADOLESCENT; ADULT; CHILD; DEPRESSIVE DISORDER; EPILEPSY; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEUROTRANSMITTER AGENTS; PITUITARY-ADRENAL SYSTEM; SUICIDE; YOUNG ADULT;

EID: 80052516098     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.04.059     Document Type: Review

References (88)

1. Christensen J., Vestergaard M., Mortensen P., Sidenius P., Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007, 6:693-698.
2. Jones J.E., Hermann B.P., Barry J.J., Gilliam F.G., Kanner A.M., Meador K.J. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav 2003, 4:S31-S38.
3. Tellez-Zenteno J.F., Patten S.B., Jetté N., Williams J., Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007, 48:2336-2344.
4. Kanner A.M. Suicidality and epilepsy: a complex relation that remains misunderstood and under-estimated. Epilepsy Curr 2009, 9:1-4.
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Biostatistics Statistical review and evaluation: antiepileptic drugs and suicidality May 21 2008.
6. Hesdorffer D.C., Kanner A.M. The FDA alert on suicidality and antiepileptic drugs: fire or false alarm?. Epilepsia 2009, 50:978-986.
7. Gibbons R.D., Jur K., Brown C.H., Mann J.J. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009, 66:1354-1360.
8. Olesen J.B., Hansen P.R., Erdal J., et al. Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiol Drug Saf 2010, 19:518-524.
9. Patorno E., Bohn R.L., Wahl P.M., et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010, 303:1401-1409.
10. VanCott A.C., Cramer J.A., Copeland L.A., et al. Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VS hospital system. BMC Med 2010, 8:4.
11. Arana A., Wentworth C.E., Ayuso-Mateos J.L., Arellano F.M. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010, 5(363):542-551.
12. Hesdorffer D.C., Hauser W.A., Ludvigsson P., Olafsson E., Kjartansson O. Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol 2006, 59:35-41.
13. Forsgren L., Nystrom L. An incident case referent study of epileptic seizures in adults. Epilepsy Res 1999, 6:66-81.
14. Hesdorffer D.C., Hauser W.A., Annegers J.F., et al. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000, 47:246-249.
15. Kanner A.M., Barry J.J., Gilliam F., Hermann B., Meador K.J. Anxiety disorders, sub-syndromic depressive episodes and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy?. Epilepsia 2010, 51:1152-1158.
16. Kessler R.D., Borges G., Walters E.E. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 1999, 56:617-626.
17. Sareen J., Cox B.J., Afifi T.O., et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005, 62:1249-1257.
18. Jobe P.C. Affective disorder and epilepsy comorbidity in the genetically epilepsy prone-rat (GEPR). Depression and brain dysfunction 2006, 121-157. Taylor & Francis, London. F. Gilliam, A.M. Kanner, Y.I. Sheline (Eds.).
19. Mazarati A.M., Siddarth P., Baldwin R.A., et al. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008, 131:2071-2083.
20. Hasler G., Bonwetsch R., Giovacchini G., et al. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007, 62:1258-1264.
21. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000, 57:174-180.
22. Theodore W.H., Giovacchini G., Bonwetsch R., et al. The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia 2006, 47:499-503.
23. Toczek M.T., Carson R.E., Lang L., et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003, 60:749-756.
24. Asberg M., Bertilsson L., Martensson B. Indolamine metabolites, depression and suicide. Adv Biochem Psychopharmacol 1984, 39:87-97.
25. Lester D. The concentrations of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry 1995, 28:45-50.
26. Oquendo M.A., Placidi G.P., Malone K.M., et al. Positron emission tomography of brain metabolic responses to a serotoninergic challenge and lethality of suicide attempts in major depression. Arch Gen Psychiatry 2003, 60:14-22.
27. Arango V., Underwood M.D., Gubbi A.V., Mann J.J. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 1995, 688:121-133.
28. Goodwinn F.K., Jamison K.R. Suicide. Manic-depressive illness 2007, vol. 1:247-269. Oxford Univ. Press. 2nd ed. F.K. Goodwinn, K.R. Jamison (Eds.).
29. Arango V., Huang Y.Y., Underwood M.D., Mann J.J. Genetics of the serotonergic system in suicidal behavior. J Psychiatr Res 2003, 37:375-386.
30. Zobel A., Wellmer J., Schulze-Rauschenbach S., et al. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. Eur Arch Psychiatry Clin Neurosci 2004, 254:303-311.
31. Plotsky P.M., Owens M.J., Nemeroff C.B. Psychoneuroendocrinology of depression: hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am 1998, 21:293-307.
32. Mazarati A.M., Shin D., Kwon Y.S., et al. Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis 2009, 34:457-461.
33. Kumar G., Couper A., O'Brien T.J., et al. The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology 2007, 32:834-842.
34. Bunney W.E., Fawcett J.A. Possibility of a biochemical test for suicidal potential: an analysis of endocrine studies prior to three studies. Arch Gen Psychiatry 1965, 13:232-239.
35. Jokinen J., Nordström P. HPA axis hyperactivity and attempted suicide in young adult mood disorder inpatients. J Affect Disord 2009, 116:117-120.
36. Coryell W. DST abnormality as a predictor of course in major depression. J Affect Disord 1990, 19:163-169.
37. Norman W.H., Brown W.A., Miller I.W., Keitner G.I., Overholser J.C. The dexamethasone suppression test and completed suicide. Acta Psychiatr Scand 1990, 81:120-125.
38. Coryell W., Schlesser M. The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001, 158:748-753.
39. Jokinen J., Mårtensson B., Nordström A.L., Nordström P. CSF 5-HIAA and DST non-suppression -independent biomarkers in suicide attempters?. J Affect Disord 2008, 105:241-245.
40. Brunner J., Bronisch T. Neurobiological correlates of suicidal behavior. Fortschr Neurol Psychiatr 1999, 67:391-412.
41. Brunson K.L., Eghbal-Ahmadi M., Baram T.Z. How do the many etiologies of West syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis. Brain Dev 2001, 23:533-538.
42. Sapolsky R.M. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000, 15(48):755-765.
43. Sapolsky R.M. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000, 57:925-935.
44. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 15(22):3251-3261.
45. Bowley M.P., Drevets W.C., Ongur D., Price J.L. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002, 52:404-412.
46. Rajkowska G., Miguel-Hidalgo J.J., Wei J., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999, 45:1085-1098.
47. Cotter D.R., Pariante C.M., Everall I.P. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001, 55:585-595.
48. Cotter D., Mackay D., Landau S., Kerwin R., Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001, 58:545-553.
49. Cotter D., Mackay D., Chana G., Beasley C., Landau S., Everall I.P. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002, 12:386-394.
50. Öngür D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998, 95:13290-13295.
51. Crossin K.L., Tai M.H., Krushel L.A., Mauro V.P., Edelman G.M. Glucocorticoid receptor pathways are involved in the inhibition of astrocyte proliferation. Proc Natl Acad Sci USA 1997, 94:2687-2692.
52. Heckers S., Stone D., Walsh J., Shick J., Koul P., Benes F.M. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 2002, 59:521-529.
53. Brambilla P., Perez J., Barale F., Schettini G., Soares J.C. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003, 8:721-737.
54. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005, 10:808-819.
55. Choudary P.V., Molnar M., Evans S.J., et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005, 25(102):15653-15658.
56. Sequeira A., Mamdani F., Ernst C., et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009, 11(4(8)):e6585.
57. Kanner A.M. Depression and epilepsy: How can we explain their bidirectional relation?. Epilepsia 2011, 52(Suppl. 1):21-27.
58. Mason G.F., Sanacora G., Hundal R., et al. Preliminary evidence of reduced cortical GABA synthesis rate in major depression. Soc Neurosci Abstr 2001, 142.6.
59. Sanacora G., Mason G.F., Rothman D.L., Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002, 159:663-665.
60. Thome-Souza S., Kuczynski E., Assumpcao F., et al. Which factors may play a pivotal role on determining the type of psychiatric disorder in children and adolescents with epilepsy?. Epilepsy Behav 2004, 5:988-994.
61. Plioplys S., Dunn D.W., Caplan R. 10-year research update review: psychiatric problems in children with epilepsy. J Am Acad Child Adolesc Psychiatry 2007, 46:1389-1402.
62. Brent D.A. Overrepresentation of epileptics in a consecutive series of suicide attempters seen at a children's hospital, 1978-1983. J Am Acad Child Psychiatry 1986, 25:242-246.
63. Caplan R., Siddarth P., Gurbani S., Hanson R., Sankar R., Shields W.D. Depression and anxiety disorders in pediatric epilepsy. Epilepsia 2005, 46:720-730.
64. Kanner A.M. Is major depression a neurologic disorder with psychiatric symptoms?. Epilepsy Behav 2004, 5:636-644.
65. Achenbach T.M., Rescorla L.A. Manual for ASEBA School-Age Forms & Profiles 2001, University of Vermont, Research Center for Children, Youth, & Families, Burlington, VT.
66. Kovacs M. CDI 1992, Multi-Health Systems, Inc., North Tonawanda, NY.
67. Achenbach T.M., Dumenci L. Advances in empirically based assessment: revised cross-informant syndromes and new DSM-oriented scales for the CBCL, YSR, and TRF: comment on Lengua, Sadowksi, Friedrich, and Fischer (2001). J Consult Clin Psychol 2001, 69:699-702.
68. Saylor C.F., Finch A.J., Spirito A., Bennett B. The children's depression inventory: a systematic evaluation of psychometric properties. J Consult Clin Psychol 1984, 52:955-967.
69. Barry J.J., Ettinger A.B., Friel P., et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 2008, 13(Suppl. 1):S1-S29.
70. Amann B., Grunze H. Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia 2005, 46(Suppl. 4):26-30.
71. Donovan S.J., Stewart J.W., Nunes E.V., et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000, 157:818-820.
72. Salpekar J.A., Conry J.A., Doss W., et al. Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder. Epilepsy Behav 2006, 9:327-334.
73. Emslie G.J., Rush A.J., Weinberg W.A., et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997, 54:1031-1037.
74. Keller M.B., Ryan N.D., Strober M., et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001, 40:762-772.
75. Emslie G.J., Heiligenstein J.H., Wagner K.D., et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002, 41:1205-1215.
76. Wagner K.D., Ambrosini P., Rynn M., et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003, 290:1033-1041.
77. Wagner K.D., Robb A.S., Findling R.L., Jin J., Gutierrez M.M., Heydorn W.E. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004, 161:1079-1083.
78. Wagner K.D., Jonas J., Findling R.L., Ventura D., Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 2006, 45:280-288.
79. March J.S., Silva S., Petrycki S., et al. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007, 64:1132-1143.
80. Kanner A.M. Epilepsy, suicidal behaviour, and depression: do they share common pathogenic mechanisms?. Lancet Neurol 2006, 5:107-108.
81. Gilliam F., Kuzniecky R., Faught E., Black L., Carpenter G., Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 1997, 38:233-236.
82. Salgado-Commissariat D., Alkadhi K.A. Serotonin inhibits epileptiform discharge by activation of 5-HT1A receptors in CA1 pyramidal neurons. Neuropharmacology 1997, 36:1705-1712.
83. 18F]MPPF-PET study. Brain 2004, 127:900-913.
84. Lesch K.P., Mossner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders?. Biol Psychiatry 1998, 44:179-192.
85. Hranilovic D., Stefulj J., Schwab S., et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatry 2004, 55:1090-1094.
86. Hecimovic H., Stefulj J., Cicin Sain L., Demarin V., Jernej B. Association of serotonin transporter promoter (5-HTTLPR) and intron 2 (VNTR-2) polymorphisms with treatment response in temporal lobe epilepsy. Epilepsy Res 2010, 91:35-38.
87. Mayberg H.S., Lozano A.M., Voon V., et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
88. Gilliam F., Hecimovic H., Sheline Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav 2003, 4(Suppl.):S26-S30.